Mazen Hanna, MD
Cardiovascular Disease · Cleveland, OHNPI 1033128731
Payments from drug & device makers
Across 208 payments — averaging $7750.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$659K
- AstraZeneca$408K
- Alnylam Pharmaceuticals Inc.$319K
- American Regent$121K
- Ionis Pharmaceuticals, Inc.$84K
- Astrazeneca UK Limited$5K
- plus $16K from 17 others
Across 43 payments — averaging $1150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$49K
What the payments were for
- Consulting fees$114,14555%
- Speaking & faculty fees$49,15824%
- Travel & lodging$40,36919%
- Food & beverage$4,1742%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 61 | $659,223 |
| AstraZeneca(2 entities) | 21 | $408,358 |
| Alnylam Pharmaceuticals Inc. | 49 | $318,819 |
| American Regent | 33 | $120,868 |
| Ionis Pharmaceuticals, Inc. | 9 | $84,015 |
| Astrazeneca UK Limited | 4 | $4,603 |
| Eidos Therapeutics, Inc. | 2 | $3,883 |
| Novo Nordisk AS | 1 | $3,750 |
| Akcea Therapeutics, Inc. | 1 | $3,175 |
| Novo Nordisk | 1 | $3,100 |
| Abbott | 6 | $439 |
| Impulse Dynamics (USA) Inc. | 3 | $332 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $214 |
| Cvrx, Inc. | 1 | $169 |
| Paragonix Technologies, Inc. | 3 | $160 |
| Abiomed | 2 | $149 |
| Bridgebio Pharma, Inc. | 1 | $143 |
| Boehringer Ingelheim | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Scpharmaceuticals Inc. | 1 | $115 |
| Lilly USA, LLC | 2 | $91 |
| Life Molecular Imaging Ltd | 1 | $90 |
| Kestra Medical Technology Services, Inc. | 1 | $63 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,612,008 in reported general payments places this provider in the 95th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 740 | $18,205,473 |
| VyndaqelTafamidis Meglumine | 91 | $1,974,070 |
| JardianceEmpagliflozin | 203 | $257,181 |
| EliquisApixaban | 143 | $165,477 |
| EntrestoSacubitril/Valsartan | 117 | $154,074 |
| FarxigaDapagliflozin Propanediol | 63 | $80,753 |
| XareltoRivaroxaban | 25 | $32,458 |
| Eplerenone | 66 | $5,864 |
| Torsemide | 147 | $4,052 |
| Metoprolol Succinate | 157 | $2,517 |
| Diflunisal | 23 | $2,158 |
| Spironolactone | 305 | $1,705 |
| Amiodarone Hcl | 36 | $1,592 |
| Digoxin | 80 | $1,025 |
| Atorvastatin Calcium | 82 | $886 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $659,223 | $20,345,020974 claims |
| Boehringer IngelheimJardiance | $125 | $257,181203 claims |
| AstraZenecaFarxiga | $408,358 | $80,75363 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 827 cardiovascular disease providers in Ohio.
Other cardiovascular disease in Cleveland
- Samir KapadiaCleveland$11.1M
- Steven NissenCleveland$5.3M
- Milind DesaiCleveland$5M
- Abraham LincoffCleveland$3.6M
- Carlos HubbardCleveland$3.1M
- Guilherme AttizzaniCleveland$2.8M
- Wai Hong TangCleveland$2.2M
- Daniel CantillonCleveland$1.3M
- Oussama WazniCleveland$665K
- Wael JaberCleveland$605K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.